The United Kingdom High Court of Justice issued a decision in favour of Teva Pharmaceutical Industries Ltd in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc.

Generics (UK) Limited commenced the proceeding in the UK to seek the revocation of European Patent (UK) 762,888, a patent for Copaxone (glatiramer acetate injection) expiring May 23, 2015, and to obtain a declaration that its proposed generic version of Copaxone  would not infringe the ‘888 patent. The High Court specifically determined that the asserted claims of the ‘888 patent were valid, and also declined to issue a declaration that Generics UK’s proposed generic version of Copaxone  would not infringe the ‘888 patent.

Any potential generic version of Copaxone  would require a marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) before it could be commercialized.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients.